# **Cancer's Special Pro-survival Genes**

Potential Conditional Lethal Genes in T cell Acute Lymphoblastic Leukaemia

# Gina Elsayed Abdelaal\*, Timothy Barrow, Dr Gordon Strathdee

# Introduction

T cell lymphoblastic leukaemia is a rare form of blood cancer. It is responsible for 15% of adult cases and 25% of pediatric cases of lymphoblastic leukaemia. If left untreated the disease progresses quickly and may be fatal within a few months.

In the past cancer was thought to be a result of changes in the DNA sequence of a gene, however it is now understood that other factors can play a role in disease progression such as DNA methylation. A gene's CpG island acts as a switch, when it is methylated the gene will be switched off and when it is left unmethylated the gene will be switched on See figure 1.

Cancer occurs when normal cells lose control over their gene expression, which may be due to abnormal methylation. There are genes that are exclusively expressed by cancer cells known as conditional lethal genes. These genes can allow cells with genetic mutations to survive. TUSC3 is a conditional lethal gene, so it is methylated (switched off) in normal conditions. Previous work on B cell lymphoblastic leukaemia has shown that when TUSC3 is unmethylated (switched on) it allows cells that have the ETV6/ RUNX1 genetic fusion to survive. TUSC3 has a similar role in T cell lymphoblastic leukaemia as it allows cells with the SIL-TAL1 fusion escape cell death. This project will mainly focus on 2 potential conditional lethal genes : PTPRK and FAT1.

# Aims

- Obtain the methylation levels of 2 conditional lethal genes FAT1 and PTPTRK in T cell patient samples and cell lines
- Compare results to known methylation levels of 2 other conditional lethal genes SPI1 and TUSC3
- See if there is any connection between methylation levels and the presence of the SIL-TAL1 gene fusion.

CpG island methlated	Gene expression blocked		
CpG island unmethyalted	Gene expressed	<b>®</b>	

Figure 1: When CpG island is methylated gene is expressed, when CpG is unmethylated gene is not expressed.

**Bisulphite modification** The DNA must be bisulphite modified. The aim of this technique is to deaminate unmethylated cytosines using sodium bisulphite . A methylated cytosines remain a cytosine. The unmethyaled cytosine becomes a thymidine.

Assay Optimisation and PCR PCR amplifies the section of DNA we are investigating. New primers were designed using primer design software. The purpose of the optimization assay is to find the conditions (MgCl2 concentration and annealing temperature) that give the largest quantity of DNA.

Pyrosequencing Pyrosequencing is used to quantify methylation along the amplified DNA. It is sequencing by synthesis technique. The sequence is entered into the pyrosequencing software. The end result is a pyrogram which gives the methylation levels of the DNA sample. See figure 2 for pyrogram.

	A3 : TTCCCCR
	3000
	2500
	2000
	1500
	1000
	500
	0
1	

Figure 2: Pyrogram for FAT1 gene. 3% and 4% represent the levels of methylation at the gene's first and second CpG sites

### Results


For both genes there was a lot of variation in the methylation levels; some samples had higher methylation statuses and some had lower as seen in figure 3.

FAT1 gene results Results for the correlation test for FAT1 showed that there was a weak negative correlation between FAT1 and TUSC3 and a weak positive correlation between FAT1 and SPI1, both were statistically insignificant. When looking at the samples with the SIL-TAL1 fusion there was a stronger positive correlation between FAT1 and SPI1 and a stronger negative correlation between FAT1 and TUSC3, but it was still statistically insignificant. 3 out of 5 of the samples with lower methylation levels had a deletion in the CDKN1B gene, this may be just a coincidence or it may have some significance.

PTPRK gene results Results for PTPRK show a positive correlation with TUSC3 and a negative correlation with SPI1 both were statistically insignificant. The results were the same for the SIL-TAL fusion samples.

# **Student number: 140071292 School of Biomedical science** Email:G.Elsayed1@newcastle.ac.uk

### **Methods**



AT1 TUSC3 84.81 35.4775 88.675 1.875 12.865 12.25 49.82 6.6075 39.9025 71.3 62.67	70.13 71.85 20.94 61.615 84.89 70.725 58.3 54.04 78.39 27.1 38.53	SPI1 5.065 5.405 10.415 11.185 12.77 22.24 24.17333333 33.555 58.28 66.97 75.405	PTPRK	TUSC     3.964     4.924     5.04     14.82     20.16     21.112     29.592     48.708     71.508     78.882     80.132	3 SPI1   61.615 54.04   54.04 71.85   65.55 65.37   4.35 78.46   78.46 84.89   78.39 20.94   38.53 38.53	11.185 33.555 5.405 88.21 84.25 91.53 86.795 12.77 58.28 10.415 75.405
35.4775 88.675 1.875 12.865 12.25 49.82 6.6075 39.9025 71.3 62.67	71.85 20.94 61.615 84.89 70.725 58.3 54.04 78.39 27.1 38.53	5.405 10.415 11.185 12.77 22.24 24.17333333 33.555 58.28 66.97		4.924 5.04 14.82 20.16 21.112 29.592 48.708 71.508 78.882	54.04 71.85 6.55 65.37 4.35 78.46 84.89 78.39 78.39	33.555 5.405 88.21 84.25 91.53 86.795 12.77 58.28 10.415
88.675 1.875 12.865 12.25 49.82 6.6075 39.9025 71.3 62.67	20.94 61.615 84.89 70.725 58.3 54.04 78.39 27.1 38.53	10.415 11.185 12.77 22.24 24.17333333 33.555 58.28 66.97		5.0414.8220.1621.11229.59248.70871.50878.882	71.85 6.55 65.37 4.35 78.46 84.89 78.39 20.94	5.405 88.21 84.25 91.53 86.795 12.77 58.28 10.415
1.875 12.865 12.25 49.82 6.6075 39.9025 71.3 62.67	61.615 84.89 70.725 58.3 54.04 78.39 27.1 38.53	11.185 12.77 22.24 24.17333333 33.555 58.28 66.97		14.82 20.16 21.112 29.592 48.708 71.508 78.882	6.55     65.37     4.35     78.46     84.89     78.39     20.94	88.21 84.25 91.53 86.795 12.77 58.28 10.415
12.865 12.25 49.82 6.6075 39.9025 71.3 62.67	84.89 70.725 58.3 54.04 78.39 27.1 38.53	12.77 22.24 24.17333333 33.555 58.28 66.97		20.16 21.112 29.592 48.708 71.508 78.882	65.37 4.35 78.46 84.89 78.39 20.94	84.25 91.53 86.795 12.77 58.28 10.415
12.25 49.82 6.6075 39.9025 71.3 62.67	70.725 58.3 54.04 78.39 27.1 38.53	22.24 24.17333333 33.555 58.28 66.97		21.112 29.592 48.708 71.508 78.882	4.35 78.46 84.89 78.39 20.94	91.53 86.795 12.77 58.28 10.415
49.82 6.6075 39.9025 71.3 62.67	58.3 54.04 78.39 27.1 38.53	24.17333333 33.555 58.28 66.97		29.592 48.708 71.508 78.882	78.46 84.89 78.39 20.94	86.795 12.77 58.28 10.415
6.6075 39.9025 71.3 62.67	54.04 78.39 27.1 38.53	33.555 58.28 66.97		48.708 71.508 78.882	84.89 78.39 20.94	12.77 58.28 10.415
39.9025 71.3 62.67	78.39 27.1 38.53	58.28 66.97		71.508 78.882	78.39 20.94	58.28 10.415
71.3 62.67	27.1 38.53	66.97				
62.67	<mark>38.53</mark>			80.132	<u>38.53</u>	
		75.405				, 5, , , , , , ,
33.22	65.40	a da anti-anti-anti-anti-anti-anti-anti-anti-		88.39	70.13	5.065
JUILE	07.49	78.10666667				
79.5	65.37	84.25		With SIL TAL fusion		
81.79	78.46	86.795	PTPRK	TUSC	3 SPI1	
28.55	6.55	88.21		7.934	85.075	6.695
5.9075	4.35	91.53		20.476	61.01	25.01
				25.878	70.225	13.16
With SIL-T	TAL fusio	n		39.63	24.67	30.21
AT1 TUSC3	S	SPI1				
38	6.695	85.075				
43.59	13.16	70.225				
61.335	30.21	24.67				
81.8275	25.01	61.01				
88.8375	8.025	87.14125				
39.775	29.22	32.86				

		L-TAL fusio	า		Witho	ut SIL-TAL fusion	
FAT1	TUSC3	SP	1	PTPRK	TUS	SC3 SPI1	
	84.81	70.13	5.065		3.964	61.615	11.185
	<mark>35.4775</mark>	71.85	5.405		4.924	54.04 <mark></mark>	<mark>33.555</mark>
	88.675	<mark>20.94</mark>	10.415		5.04	71.85	5.405
	1.875	61.615	11.185		14.82	6.55	88.21
	12.865	84.89	12.77		<mark>20.16</mark>	65.37	84.25
	12.25	70.725	22.24		21.112	4.35	91.53
	40.02	50.0	4 4 7 2 2 2 2 2 2 2		29.592	78.46	86.795
	49.82		24.17333333		48.708	84.89 <b></b>	12.77
	6.6075	54.04	33.555		71.508	78.39	58.28
	39.9025	78.39	58.28		78.882	20.94	10.415
	71.3	27.1	66.97		80.132	38.53	75.405
	62.67	<mark>38.53</mark>	75.405		88.39	70.13	5.065
	33.22	65.49	78.10666667				
	79.5	65.37	84.25		With	SIL TAL fusion	
	81.79	78.46	86.795	PTPRK	TUS	SC3 SPI1	
	28.55	6.55	88.21		7.934	85.075	6.695
	5.9075	4.35	91.53		20.476	61.01	<mark>25.01</mark>
	5.5075	4.55	51.55		25.878	70.225	<mark>13.16</mark>
	With SI	TAL fusion			39.63	24.67	<u>30.21</u>
C A T 1	TUSC3		1				
FAT1	38	SP 6.695	85.075				
			70.225				
	43.59 61.335	13.16 30.21					
			24.67				
	81.8275	25.01	61.01				
	88.8375	8.025	87.14125				
	39.775	29.22	32.86				
•						Methylation lev diate methylatio	

high methylation

# Conclusion

The two potential conditional lethal genes have a correlation with TUSC3 and SPI1, but it was not statistically significant, so it might be due to chance. This means that the methylation levels for these genes may have no effect on the survival of cells with the SIL-TAL fusion. Limitations of this project were that T cell ALL is a rare disease, so few samples were available for testing. To confirm findings this needs to be repeated in a larger study, which may give a higher statistical significance. The results that may be expected based on this project are that FAT1 expression is blocked as it has a negative correlation with TUSC3 a conditional lethal gene, and PTPRK expression is enhanced as it has a positive correlation with TUSC3. Potentially we could take advantage of this while designing a targeted cancer therapy.

### Acknowledgements:

with the lab work. pyrosequencer.



I would like to thank Newcastle University for funding my summer project and Dr Gordon Strathdee for allowing me to participate in this project and Timothy Barrow for all his help

This project would not have been possible without the Sir James Spence Institute allowing access to their labs and the Campus for Aging and Vitality for allowing access to their